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CD41 T Cell±Mediated Tumor Rejection Involves
Inhibition of Angiogenesis that Is Dependent on
IFNg Receptor Expression by Nonhematopoietic Cells
presented by MHC class II molecules on the APC. This
results in a reciprocal activation of APC and T cells by
involvement of CD40/CD40-ligand interaction (Bennett
et al., 1998; Ridge et al., 1998; Schoenberger et al.,
1998). (2) CD41 T cells are necessary for maintenance
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of CTL (Ossendorp et al., 1998), e.g., by providing cyto-
kines such as IL-2. (3) In several tumor models, it has
been shown that CD41 T cells are needed in the effectorSummary
phase of an antitumor immune response against MHC
class II2 tumors (Greenberg et al., 1981; Fujiwara et al.,Immunity against MHC class II2 tumors can be medi-
ated by CD41 T cells in the effector phase through 1984; Greenberg et al., 1985; Hock et al., 1991; Dranoff
et al., 1993; Hock et al., 1993; Monach et al., 1995; Hungan unknown mechanism. We show that this is IFNg
dependent but does not require IFNg receptor (IFNgR) et al., 1998). This was either shown by adoptive transfer
of CD41 T cells to tumor bearing mice and demonstra-expression on tumor cells, T cells, or other hematopoi-
etic cells and that IFNgR expression is not necessary in tion of tumor rejection (Greenberg et al., 1985) or by
depletion of CD41 T cells in immunized mice beforethe priming phase. However, tumor immunity requires
IFNgR expression on nonhematopoietic cells in the challenge, showing that mice without CD41 T cells were
unable to reject the challenge tumor (Dranoff et al., 1993;effector phase and involves inhibition of tumor-induced
angiogenesis. This shows that an effective anti-tumor Hung et al., 1998). In these models, CD81 T cells were
not needed at all for tumor rejection or at least part ofresponse involves communication between CD41 T
cells and nonhematopoietic cells, most likely within the mice rejected the tumor in their absence. Because
it is unlikely that CD41 T cells directly recognize MHCthe tumor stroma, and that tumor immunity must not
entirely rely on direct tumor cell killing. class II2 tumors, it has been proposed that they induce a
delayed type hypersensitivity (DTH)-like reaction during
which inflammatory cells like macrophages, granulo-Introduction
cytes, or natural killer (NK) cells are attracted and acti-
vated by CD41 T cells and kill the tumor cells (Greenberg,Most tumor cells express MHC class I but not class II
molecules and carry antigens that potentially can serve 1991; Hung et al., 1998). For example, depletion of CD41
T cells resulted in abrogation of tumor rejection correlat-as rejection antigens. CD81 T cells usually recognize
target antigens in an MHC class I±restricted fashion and ing with the absence of tumor infiltrating macrophages
(CR31 cells) (Hock et al., 1991). However, direct tumorhave the ability to lyse tumor cells by direct cell-to-
cell contact, whereas CD41 T cells usually recognize cell killing by CD41 T cell±activated innate effector cells
in vivo has not been demonstrated.antigens presented by MHC class II molecules and only
rarely have the potential to kill tumor cells. Therefore, it It is likely that cytokines produced by effector CD41
T cells are important for tumor rejection. IFNg is a keyis reasonable to assume that CD81 cytolytic T lympho-
cytes (CTL) are important effector cells during tumor cytokine in cell-mediated immunity that is produced
mainly by CD41 T helper 1 (Th1), CD81 T, and NK cellsrejection. This view is supported by a number of experi-
mental (Schreiber, 1999) and clinical data (Boon et al., (Bach et al., 1997; Boehm et al., 1997). It has multiple
biological activities on various cell types, consistent with1994).
An unresolved question in tumor immunology is how the observation that the IFNg-receptor (IFNgR) is ex-
pressed on almost all cell types (Valente et al., 1992;CD41 T cells mediate tumor rejection. It is well known
that CD41 T cells are often necessary for development Farrar and Schreiber, 1993). A role of IFNg for tumor
rejection has been demonstrated (Dighe et al., 1994).of tumor immunity following immunization with tumor
cells (Dranoff et al., 1993; Huang et al., 1994; Monach IFNg could have direct effects on tumor cells by (1) its
et al., 1995; Qin et al., 1998) or peptide antigens derived cytotoxic activity on some tumor cells (e.g., together
from the tumor (Ossendorp et al., 1998). Three possibili- with TNF) (Williamson et al., 1983; Fransen et al., 1986),
ties of how CD41 T cells contribute to the development (2) upregulating MHC expression and thereby increasing
of tumor immunity have been postulated: (1) CD41 T tumor cell recognition and elimination (Dighe et al.,
cells are needed during the immunization (priming) 1994), or (3) inducing expression of angiogenesis inhibi-
phase and help CTL to develop (Qin et al., 1998). There tors, like IP-10, by tumor cells (Coughlin et al., 1998).
is increasing evidence that CTL are often activated by Alternatively, IFNg may act in an immunoregulatory fash-
antigen-presenting cells (APC), which take up, process, ion and be important for Th1 development (Mosmann
and present antigens of the tumor by MHC class I mole- and Coffman, 1989) or activation of innate effector cells
cules (cross-priming) (Huang et al., 1994; Cayeux et al., involved in tumor rejection (Murray et al., 1985). Yet
1997). For CTL priming, APC have to receive signals another possibility is that IFNg produced by T cells acts
from CD41 T cells that have recognized tumor antigens on nonhematopoietic cells within the tumor, which then
indirectly contributes to tumor rejection. Here we dem-
onstrate that an essential requirement for CD41 T cell±* To whom correspondence should be sent (e-mail: zhihai@
mdc-berlin.de). mediated tumor immunity is IFNg production by T cells
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cells was not induced by IFNg (data not shown). There
was no difference in the in vitro proliferation rate be-
tween the IFNg-responsive and -unresponsive cells,
even when 0.5 to 500 ng/ml of IFNg were added into
the culture medium (data not shown).
To analyze whether IFNgR expression by tumor cells
alters their tumorigenicity, 2 3 105 or 13 106 Mc51.9,
Mc51.9-m, and Mc51.9-gR cells were injected into
IFNgR1/2 mice. Mc51.9 and Mc51.9-m cells grew with
similar kinetics (Figures 2a and 2b). The growth of
Mc51.9-gR cells was delayed in comparison to Mc51.9
or Mc51.9-m cells, reminiscent of results by Dighe et al.
(1994). However, eventually all mice developed a tumor.
In parallel, Mc51.9, Mc51.9-m, and Mc51.9-gR cells were
injected into IFNgR2/2 mice. As shown in Figures 2c and
2d, tumors grew with almost identical kinetics regard-
less of IFNgR expression by the tumor cells. Similar
results were obtained when tumor lines Mc29.2 and
Mc54.1 and their IFNgR-expressing variants were used
(data not shown). This indicated that IFNgR expression
by host cells was a prerequisite for the difference of
tumor growth between IFNg-responsive and -unrespon-
sive tumor cells.
Generation of Tumor Immunity Requires IFNgR
Expression by Host but Not Tumor Cells
Figure 1. Functional Expression of IFNgR in Cell Line Mc51.9 De- To compare the relative importance of IFNg respon-
rived from an IFNgR2/2 Mouse siveness of tumor and host cells for generation of tumor
(a) Cell surface IFNgR expression. Mock-transfected Mc51.9-m (left) immunity, IFNgR1/2 or IFNgR2/2 mice were immunized
and IFNgR plasmid-transfected Mc51.9-gR cells (right) were stained with irradiated Mc51.9-gR or Mc51.9-m cells or as con-
with an isotype-matched control mAb (blue) or the anti-IFNgR mAb
trol left untreated and 2 weeks later were contralaterallyGR-20 in the absence (red) or presence of 25 ng/ml IFNg (green).
challenged with increasing numbers of parental tumorPE-labeled rabbit anti-rat IgG2a was used as secondary mAb.
cells. IFNgR1/2 mice immunized with Mc51.9-gR cells(b) IFNg induced upregulation of MHC class I expression on Mc51.9-
gR cells. Tumor cells were cultured for 24 hr in the absence (red) almost invariably rejected the Mc51.9 cell challenge (Fig-
or presence of 25 ng/ml IFNg (green) and stained with FITC-labeled ures 3a and 3b). Immunization of IFNgR2/2 mice with
mAb against H-2Db (upper) or H-2Kb (lower). A FITC-labeled isotype- Mc51.9-gR cells did not induce rejection of the challenge
matched control mAb was used as control (blue).
tumor, demonstrating that generation of tumor immunity
required IFNgR expression on host cells. Furthermore,
whereas IFNgR2/2 mice immunized with Mc51.9-m cells
and IFNgR expression by nonhematopoietic cells, which
were unable to reject Mc51.9 cells, IFNgR1/2 mice immu-
results in inhibition of tumor-induced angiogenesis. nized with Mc51.9-m cells rejected Mc51.9 cells as effi-
ciently as those immunized with Mc51.9-gR cells, dem-
Results onstrating that IFNgR expression by tumor cells used
for immunization contributed little to tumor immunity in
Tumorigenicity of IFNgR1 and IFNgR2 Tumor Cells this model (Figures 3c and 3d). Challenge of immunized
To analyze the mechanism by which CD41 T cells medi- IFNgR1/2 mice with an unrelated tumor did not lead
ate tumor rejection and the relative contribution of IFNgR to tumor rejection, indicating that immunity was tumor
expression by tumor and different host cells, we estab- specific (data not shown).
lished tumor models that allowed us to analyze the rejec- To confirm the data with other tumors and exclude
tion of IFNgR1 and IFNgR2 tumor cells in IFNgR1/2 and possible cell culturing artifacts, IFNgR1/1 and IFNgR2/2
IFNgR2/2 mice. Tumor cell lines (e.g., Mc51.9) induced mice were grafted with tumor fragments derived from
by MCA in 129/Sv/Ev IFNgR2/2 mice (H2b) did not ex- hosts bearing primary MCA-induced tumors. Twelve to
press IFNgR molecules. After transfection with an IFNgR fourteen days later, tumors were surgically removed, and
expression plasmid (resulting in Mc51.9-gR cells) but after another week a fragment of the same tumor pas-
not a control plasmid (resulting in Mc51.9-m cells), the saged in nude mice was grafted onto the mice at a dis-
cells expressed IFNgR on their surface (Figure 1a). Stain- tant site. Altogether, five tumors (two from IFNgR1/1 and
ing with anti-IFNgR mAb could be blocked by preincuba- three from IFNgR2/2 mice) were analyzed. In IFNgR1/1
tion of the cells with IFNg. Mc51.9 cells express MHC mice, one of the two IFNgR1 tumors and two of the
class I molecules (both H-2Db and H-2Kb) (Figure 1b) three IFNgR2 tumors were rejected (Figure 3e). In
and are negative for MHC class II (data not shown). The IFNgR2/2 mice, all five tumors grew progressively re-
IFNgR was functionally expressed by Mc51.9-gR cells gardless of whether their origin was from IFNgR1/1 or
because exposure of these cells to IFNg upregulated ex- IFNgR2/2 mice. Thus, host but not tumor cells must
pression of MHC class I molecules (Figure 1b). IFNg did express the IFNgR for development of tumor immunity.
not change MHC class I expression on Mc51.9-m cells. Furthermore, these results indicated that IFNgR expres-
sion was not necessary for tumor immunity on both theThe expression of MHC class II molecules on Mc51.9-gR
Tumor Immunity Involves Antiangiogenesis
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Figure 2. IFNgR Expression by Tumor Cells
Reduces Tumorigenicity in IFNgR1/2 but Not
in IFNgR2/2 Mice
IFNgR1/2 and IFNgR2/2 mice (5±6 mice/
group) were s.c. injected with 2 3 105 (a and
c) or 1 3 106 (b and d) Mc51.9 (open circles),
Mc51.9-m (closed circles), or Mc51.9-gR cells
(closed triangles). Tumor growth was moni-
tored. Representative results from one out
of four experiments with similar results are
shown.
tumor cells used for immunization and those used for involved in the effector phase (Figure 4). Half of the mice
depleted of CD81 T cells rejected the challenge tumor,challenge.
half did not. Therefore, CD81 T cells appear to contribute
to tumor rejection, but at least in part of the mice, tumorTumor Immunity Requires CD41 T Cells
rejection occurred in their absence.in the Effector Phase
Since the results above had shown that IFNgR expres-
sion by tumors contributes little to the generation of T Cell Responses to the Mc51.9 Tumor Are Not
Impaired in IFNgR2/2 Micetumor immunity, subsequent experiments were per-
formed with the IFNgR2 tumor cell line Mc51.9. The To investigate whether the T cell response to the tumor
was impaired in IFNgR2/2 mice, spleen cells fromcontribution of T cell subsets in the effector phase of
tumor immunity can variously be dominated by CD41 IFNgR1/2 and IFNgR2/2 mice immunized twice with
irradiated Mc51.9 cells were stimulated with tumor cell(Hung et al., 1998) or CD81 T cells (Hock et al., 1993;
Qin et al., 1998). Therefore, CD41 or CD81 T cells were lysate and proliferation was measured. T cells of immu-
nized IFNgR1/2 and IFNgR2/2 mice proliferated in re-depleted in Mc51.9-immunized IFNgR1/1 mice before
challenge. All immunized control mice but none of the sponse to the tumor cell lysate (Figure 5a). No significant
proliferation was observed with spleen cells of naivemice depleted of CD41 T cells rejected the challenge
tumor, demonstrating that CD41 T cells were critically mice. T cells from IFNgR2/2 mice in fact proliferated
Figure 3. Tumor Immunity Can Be Generated
in IFNgR1/2 but Not in IFNgR2/2 Mice
(a±d) IFNgR1/2 (open symbols) and IFNgR2/2
mice (closed symbols) were left untreated
(circles) or immunized (triangles) with 2 3 105
irradiated Mc51.9-gR (a and b) or Mc51.9-m
cells (c and d) and 2 weeks later were contra-
laterally challenged with 1 3 105 (a and c) or
5 3 105 (b and d) Mc51.9 cells. Each group
consisted of 5±6 mice. Similar results were
obtained in three other experiments. For na-
ive control mice, the same experiment is
shown in (a) and (c) or (b) and (d), respectively.
(e) Tumors were induced by MCA (1±2 in
IFNgR1/1 and 3±5 in IFNgR2/2 mice). At a size
of 11±12 mm, tumors were isolated and tumor
fragments (4 3 4 3 4 mm) were grafted s.c.
onto IFNgR1/1 and IFNgR2/2 mice (2±3/group)
and onto a nude mouse. Tumors in IFNgR1/1
and IFNgR2/2 mice were subsequently re-
moved at day 12±14, when they reached a
size of 10 mm in diameter. One week later,
the mice were challenged with a fragment of
the same tumor (4 3 4 3 4 mm) passaged in
nude mice. Shown are the numbers of mice
that rejected the challenge tumor per total
numbers of mice. For tumor 1 and 4, the mean tumor size and standard deviation at day 12 are also shown in parenthesis. Two tumor-free
mice (asterisk) were challenged again with an unrelated tumor (tumor 5 from an IFNgR2/2 mouse), which grew progressively in both cases.
Immunity
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Mc51.9 cells and spleen cells depleted of adherent cells
were transferred into naive IFNgR1/2 and IFNgR2/2 mice.
Three days later the mice were challenged with Mc51.9
cells and tumor growth was monitored. Untreated mice
(IFNgR1/2 and IFNgR2/2) rapidly developed a tumor (Fig-
ure 6a). IFNgR2/2 mice that received spleen cells from
immunized IFNgR2/2 mice developed a tumor with simi-
lar kinetics compared to control animals. Transfer of
IFNgR2/2 spleen cells into IFNgR1/2 mice resulted in in-
hibition of tumor growth. In parallel, we transferred spleen
cells from immunized IFNgR1/2 mice into IFNgR1/2
and IFNgR2/2 mice, which then were challenged with
Mc51.9 cells. Transfer of IFNgR1/2 spleen cells into
IFNgR1/2 mice resulted in inhibition of tumor growth
(Figure 6b), a result similar to that found in the transferFigure 4. Tumor Immunity against Mc51.9 Tumor Cells Requires
of IFNgR2/2 spleen cells into IFNgR1/2 mice (Figure 6a).CD41 T Cells in the Effector Phase
Transfer of IFNgR1/2 spleen cells into IFNgR2/2 miceIFNgR1/1 mice were immunized with 2 3 105 irradiated Mc51.9 cells
and 14 days later were contralaterally challenged with 2 3 105 had no inhibitory effect on tumor growth (Figure 6b). A
Mc51.9 cells. Depletion of CD41 (closed squares) or CD81 T cells similar result was obtained when spleen cells of naive
(closed triangles) was started 3 days before the tumor challenge. or immunized IFNgR1/2 and IFNgR2/2 mice were trans-
Mice that were not T cell depleted (closed circles) and that were not
ferred into SCID mice. Transfer of spleen cells from bothimmunized (open circles) served as control. Each group consisted of
immunized IFNgR1/2 and IFNgR2/2 mice inhibited tumor8±10 mice.
growth, whereas spleen cells from naive mice in either
case had no effect (data not shown). Therefore, neither
tumor nor spleen cells but other cells of the host mustmore vigorously than those from IFNgR1/2 mice, indicat-
express IFNgR for inhibition of tumor growth. Becauseing that their activation was not impaired. Because IFNg
CD41 T cells are essential for tumor rejection in theproduction by host cells might be a prerequisite for
effector phase, the results indicate that they must nottumor immunity in IFNgR1/2 mice, we analyzed the ability
express IFNgR to inhibit tumor growth, if other host cellsof IFNgR1/2 and IFNgR2/2 mice to produce IFNg follow-
are IFNg responsive. Additionally, these experimentsing immunization with Mc51.9 cells. Similar to the pro-
showed that IFNgR expression was necessary only inliferation assay, spleen cells of immunized but not
the effector but not in the priming phase.naive IFNgR1/2 and IFNgR2/2 mice secreted substantial
amounts of IFNg when stimulated with the tumor cell
lysate (Figure 5b).
Inhibition of Tumor Growth Requires IFNgRBecause T cells in immunized IFNgR2/2 mice were
Expression on Nonhematopoietic Cellsactivated and produced IFNg, we analyzed whether T
In the following experiment, we asked whether hemato-cells homed to the challenge site. Tumors in naive
poietic cells or nonhematopoietic cells must expressIFNgR1/2 and IFNgR2/2 mice contained few CD41 T cells
IFNgR. Lethally irradiated IFNgR2/2 (Figure 6c) and4 days after tumor cell injection (Figures 5c and 5d). At
IFNgR1/2 mice (Figure 6d) were reconstituted with bonethe same time, a clearly increased number of tumor-
marrow cells from either IFNgR1/2 or IFNgR2/2 mice.infiltrating CD41 T cells was detected in challenge tu-
Eleven weeks after bone marrow transplantation, themors of immunized mice (Figures 5e and 5f). It appeared
mice were immunized and challenged with Mc51.9 cells.as if tumors in IFNgR1/2 and IFNgR2/2 mice were infil-
Normal IFNgR1/2 and IFNgR2/2 mice served as control.trated by CD41 T cells to a similar extent, but subtle
Naive and immunized IFNgR2/2 mice rapidly developeddifferences cannot be excluded. Similar results were
a tumor (Figure 6c). Among the reconstituted animals,obtained for CD81 T cells (data not shown). Mac-11
both IFNgR2/2!IFNgR2/2 mice and IFNgR1/2!IFNgR2/2(data not shown) and Gr-11 cells (Figures 5g and 5h)
mice developed a tumor with similar kinetics, demon-massively infiltrated the tumor in immunized IFNgR1/2
strating that IFNgR expression on hematopoietic cellsand IFNgR2/2 mice 4 days after challenge, indicating
was not sufficient for tumor growth inhibition. In con-that the inflammatory response to the challenge tumor
trast, while all naive IFNgR1/2 mice developed a tumorwas not dramatically impaired in IFNgR2/2 compared to
at day 17, half of the immunized mice rejected the tumorIFNgR1/2 mice. In naive mice, clearly less inflammatory
(Figure 6d). Tumor growth in IFNgR1/2!IFNgR1/2 andcells were observed in the tumor at that time point (data
IFNgR2/2!IFNgR1/2 mice was suppressed to a similarnot shown).
extent. There was no significant difference of tumor inci-
dence between immunized IFNgR1/2 mice and chimericHost Cells Other Than T Cells Must Express IFNgR
IFNgR1/2!IFNgR1/2 and IFNgR2/2!IFNgR1/2 mice. Infor Inhibition of Tumor Growth
all three cases, tumor growth was delayed and at leastBecause T cell activation and function appeared to be
part of the mice completely rejected the tumor. Thus,normal in immunized IFNgR2/2 mice and yet the mice
tumor growth inhibition required IFNgR expression bywere unable to reject a challenge tumor, we asked
nonhematopoietic cells, whereas IFNgR expression bywhether spleen cells from immunized IFNgR2/2 mice
hematopoietic cells contributed little or not at all to tu-could inhibit tumor growth if transferred into IFNgR1/2
mice. IFNgR2/2 mice were immunized with irradiated mor rejection.
Tumor Immunity Involves Antiangiogenesis
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Figure 5. T Cell Responses to the Mc51.9 Tumor Are Normal in IFNgR2/2 Mice
(a) T cell proliferation assay. IFNgR1/2 and IFNgR2/2 mice were left untreated or immunized twice with 2 3 105 irradiated Mc51.9 cells. Five
days after the second immunization, spleen cells were isolated and stimulated with Mc51.9 tumor cell lysate at a spleen:tumor cell ratio of
40:1 for 5 days (closed bars). Spleen cell cultures without tumor cell lysate served as control (open bars). Proliferation was measured by a
12 hr 3H-thymidine incorporation assay. One out of three experiments with similar results is shown.
(b) IFNg production by immune spleen cells. Spleen cells from naive or Mc51.9-immunized mice were stimulated with tumor cell lysate, and
IFNg was determined by ELISA in culture supernatants. Shown are the representative results of three experiments.
(c±f) Infiltration of CD41 T cells into challenge tumors. IFNgR1/2 and IFNgR2/2 mice were left untreated (c and d) or immunized twice with 2 3
105 irradiated Mc51.9 cells (e and f). All mice were challenged with 1 3 106 Mc51.9 cells. Four days later tumor sections were prepared and
stained for CD41 T cells. Magnification: 2003.
(g and h) Infiltration of Gr-11 cells into challenge tumors in IFNgR1/2 (g) and IFNgR2/2 (h) mice. Mice were treated as above and tumor sections
were stained with anti-Gr-1 mAb. Magnification: 2003. Results of tissue sections are representative for 3±5 tumors per group.
Tumor Immunity Involves Inhibition of Angiogenesis they were visible; however, they were unable to grow
into the tumor tissue. Correlating with the inability ofIn both immunized IFNg-R1/2 and IFNg-R2/2 mice, T
cells were activated, produced IFNg, and homed to the blood vessels to grow into the tumor in immunized
IFNgR1/2 mice, large areas in the center of the tumorchallenge site (Figure 5), and IFNgR expression was
necessary for tumor rejection only in the effector phase mass had already become necrotic at that time (Figure
7e). Thus, CD41 T cell±dependent tumor immunity in-on nonhematopoietic cells (Figure 6). Therefore, we as-
sumed that tumor immunity relied on IFNgR expression volves tumor destruction indirectly by inhibition of an-
giogenesis.by cells within the stroma of MC51.9 tumors and ana-
lyzed tumor-induced blood vessel formation in naive
and immunized IFNgR1/2 and IFNgR2/2 mice. Immuno-
histochemical analysis for the endothelial marker CD31 Discussion
showed that tumors were already well vascularized in
naive mice 4 days after inoculation. Angiogenesis typical CD41 T cells play an important role not only in the prim-
ing but also in the effector phase of immune responsesfor an established tumor was similarly seen in IFNgR1/2
and IFNgR2/2 mice (Figures 7a and 7b). In 4-day-old against MHC class II2 tumors. It has been postulated
that they induce a DTH-like reaction during which innatechallenge tumors of immunized IFNgR2/2 mice, tumor
blood vessels similar to that in naive mice were observed effector cells like macrophages (Greenberg, 1991) or NK
cells (Levitsky et al., 1994) are attracted and activated(Figures 7d and 7f). In contrast, in challenge tumors
of immunized IFNgR1/2 mice, blood vessels within the by CD41 T cell±derived cytokines and subsequently kill
the tumor cells. IFNg is produced by CD41 Th1 cellstumor mass were completely absent (Figures 7c and
7e). At the border between tumor and adjacent tissue, (Mosmann and Coffman, 1989), is required for tumor
Immunity
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Figure 6. IFNgR Expression On Nonhemato-
poietic Cells Is Essential for Inhibition of Tu-
mor Growth
(a) Adoptive transfer of tumor immunity with
spleen cells of IFNgR2/2 mice into IFNgR1/2
recipients. Spleen cells (3 3 107) from immu-
nized IFNgR2/2 mice (twice with 2 3 105 irradi-
ated Mc51.9 cells) were injected i.v. into
IFNgR1/2 or IFNgR2/2 mice. Three days later,
recipient IFNgR1/2 (open triangles), IFNgR2/2
(closed triangles), and as control, untreated
IFNgR1/2 (open circles) and IFNgR2/2 (closed
circles) mice were challenged with 1 3 106
Mc51.9 tumor cells. Numbers of mice per
group were 5±6, and shown are results from
1 out of 2 experiments with similar results.
(b) Failure of adoptive transfer of tumor immu-
nity with immune spleen cells from IFNgR1/2
into IFNgR2/2 mice. Spleen cells were pre-
pared from immunized IFNgR1/2 mice and
adoptively transferred into naive mice as de-
scribed above. Three days later, recipient
IFNgR1/2 (open squares), IFNgR2/2 (closed
squares), and as control, untreated IFNgR1/2 (open circles) and IFNgR2/2 (closed circles) mice were challenged with 1 3 106 Mc51.9 cells.
Numbers of mice per group were 8±12, and shown are results from 1 out of 2 experiments with similar results.
(c) Failure to generate tumor immunity in IFNgR1/2 bone marrow reconstituted IFNgR2/2 mice. Lethally irradiated IFNgR2/2 mice (8±10 mice/
group) were reconstituted with 5 3 106 bone marrow cells from IFNgR1/2 (closed squares with ª3º) or IFNgR2/2 donors (closed triangles).
Eleven weeks after reconstitution, mice were immunized with 2 3 105 irradiated Mc51.9 cells and challenged 2 weeks later with 1 3 106
Mc51.9 cells. Naive (closed circles) and immunized nonreconstituted IFNgR2/2 (closed squares) mice served as control.
(d) Tumor immunity can be generated in IFNgR2/2 bone marrow reconstituted IFNgR1/2 mice. IFNgR1/2 mice (8±12/group) were reconstituted
with bone marrow cells from IFNgR1/2 (open triangle) or IFNgR2/2 donors (ª3º), immunized and challenged as above. Naive (open circles)
and immunized nonreconstituted IFNgR1/2 (open squares) mice served as control.
rejection in some models (Dighe et al., 1994), and acti- et al. (1999) showed that CD41 T cell±mediated rejection
did not require IFNgR responsiveness of the tumor cells.vates macrophages (Murray et al., 1985) and NK cells
(Trinchieri and Perussia, 1985). Therefore, we analyzed The decreased tumorigenicity of IFNgR1 tumor cells in
IFNgR1/2 mice was abrogated for unknown reasons inthe mechanism by which CD41 T cells mediate tumor
rejection with specific emphasis on the role of IFNg/ IFNgR2/2 mice, demonstrating that IFNgR expression
by host cells was most important for an antitumor re-IFNgR. To this end, we established tumor models
allowing us to analyze the requirement of IFNgR expres- sponse. This was firmly established by demonstrating
that IFNgR1/2 mice could be immunized with IFNgR1 orsion on tumor and different host cells for tumor immunity
mediated by CD41 T cells and the time point when IFNgR2 tumor cells. Conversely, IFNgR2/2 mice were
severely impaired in development of tumor immunitythe IFNgR must be expressed. We describe here that the
IFNgR must be expressed in the effector but not the regardless whether they were immunized with IFNgR1
or IFNgR2 tumor cells. The fact that IFNgR expressionpriming phase of the antitumor response, that nonhema-
topoietic cells within the tumor stroma were likely the and IFNg-induced MHC upregulation was not necessary
on cells used for immunization is compatible with thetarget of IFNg, and that CD41 T cell±mediated tumor
immunity involved inhibition of angiogenesis. observation that T cells appear to be activated by
ªcross-primingº (Huang et al., 1994; Cayeux et al., 1997).Tumor cells lacking IFNgR were more tumorigenic in
IFNgR1/2 mice than transfected variants expressing the The observation that IFNgR expression was also not
necessary on challenge tumor cells indicates that IFNg-IFNgR (tumor growth did not differ in IFNgR1/2 and IFNg-
R1/1 mice). This was also observed by using tumor cells induced upregulation of MHC molecules in the effector
phase did not play a significant role for better T cellexpressing a dominant-negative IFNgR mutant gene
(Dighe et al., 1994; Coughlin et al., 1998). However, we recognition/elimination in our tumor model.
The inability of IFNgR2/2 mice to develop tumor immu-observed in several tumor models (Mc29.2, Mc51.9, and
Mc54.1) a slightly decreased tumorigenicity upon IFNgR nity most likely did not reside in the T cell compartment. It
is known already from the initial description of IFNgR2/2expression, and finally all mice developed a tumor when
IFNgR1 tumor variants were injected into naive IFNgR1/2 mice that T cell development and activation appear to
be normal in these mice (Huang et al., 1993). Addition-mice. We cannot exclude that decreased tumorigenicity
would have been more obvious when less tumor cells ally, IFNg2/2 mice, which might have a phenotype similar
to IFNgR2/2 mice, can develop immunity to some infec-were injected. Alternatively, the marginal effect of IFNgR
expression on tumor cells for their tumorigenicity could tious pathogens such as Listeria monocytogenes (Harty
and Bevan, 1995). We showed that immunization withbe due to the experimental system (use of tumors from
IFNgR2/2 mice and moderate expression of IFNgR in the tumor cells activated T cells in IFNgR2/2 as well as in
IFNgR1/2 mice as judged by T cell proliferation, IFNgvariants) or the effector mechanism during rejection. In
our model, CD41 T cells played a dominant role in the production, and homing to the challenge site. Moreover,
transfer of spleen cells from immunized IFNgR2/2 miceeffector phase of tumor rejection, and recently Mumberg
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Figure 7. Inhibition of Tumor-Induced Angio-
genesis in Immunized IFNgR1/2 but not
IFNgR2/2 Mice
Mice (3±5/group) were left untreated or immu-
nized twice with 2 3 105 irradiated Mc51.9
tumor cells and challenged one week later by
an s.c. injection of 1 3 106 Mc51.9 cells. Four
days after challenge, cryostat tumor sections
were prepared and stained with anti-CD31
mAb for endothelial cells. Shown in (a) and
(b) are tumor sections of naive IFNgR1/2 (a)
and IFNgR2/2 (b) mice. Shown in (c)±(f) are
tumor sections of immunized IFNgR1/2 (c and
e) and IFNgR2/2 (d and f) mice. Note the ne-
crotic area in the center of the tumor in immu-
nized IFNgR1/2 mice in (e). Magnification:
2003 (a±d) and 403 (e and f).
inhibited tumor growth in IFNgR1/2 mice to a similar infiltration of T cells. At least in vitro T cells produced
IFNg in response to Mc51.9 cells (Figure 5b). Whetherextent as transfer of IFNgR1/2 spleen cells. This experi-
ment also showed that IFNgR expression was not neces- tumor-infiltrating CD41 T cells also produce IFNg has
to be analyzed. In IFNgR2/2 mice, nonhematopoieticsary in the priming but only in the effector phase of the
antitumor response. cells within the tumor stroma could not respond to IFNg,
and therefore angiogenesis was not impaired and theWhile the adoptive transfer experiments indicated that
neither tumor nor T cells must express IFNgR for tumor tumor was not rejected. It is possible that IFNg directly
acted on endothelial cells that express the IFNgR (Va-immunity, it left open the question of whether other he-
matopoietic cells needed to express IFNgR. For in- lente et al., 1992). Alternatively, IFNg acted on other
cells in the tumor stroma, e.g., fibroblasts, and inducedstance, IFNg produced by CD41 T cells could be needed
for a DTH-like reaction and activate other cells such as secondary cytokines, which contributed to inhibition of
angiogenesis. For example, IFNg can induce productionNK cells or macrophages for tumoricidal activity
(Greenberg et al., 1985) or induce production of other of IP-10 and Mig by fibroblasts (Luster et al., 1985;
Farber, 1990), two chemokines known to inhibit angio-cytokines (Boehm et al., 1997). Surprisingly, bone mar-
row chimeric mice showed that IFNgR expression was genesis (Sgadari et al., 1996, 1997). We cannot yet ex-
clude the possibility that impaired tumor angiogenesisnot necessary on hematopoietic cells for tumor immu-
nity. This does not argue against innate effector cells results from tumor cell killing and reduced tumor cell±
derived angiogenic factors. However, because at theinvolved in the antitumor response, which then, how-
ever, would act in an IFNgR-independent fashion. In rim of the tumor, sufficient viable cells and blood vessel
formation were visible, we think that IFNg-producingfact, challenge tumors in IFNgR2/2 mice were infiltrated
by large numbers of Mac11 and Gr11 cells. CD41 T cells inhibited invasion of blood vessels into the
tumor.IFNgR expression by nonhematopoietic cells was of
critical importance for inhibition of tumor growth. Since The finding that CD41 T cell±mediated tumor immunity
involves inhibition of angiogenesis has several implica-its expression was required only in the effector phase,
it is likely that these cells were within the tumor stroma. tions. (1) It shows that tumor immunity, at least in models
in which CD41 T cells are essential effector cells, doesIt is well known that tumors above a critical size require
blood supply and induce the formation of blood vessels not exclusively rely on direct tumor cell killing. Inhibition
of angiogenesis is an effective way to prevent rapidin the tumor (Folkman, 1998). Only 4 days after injection
of tumor cells in naive mice, tumors were well vascu- tumor growth but is unlikely to be sufficient to lead
to complete tumor rejection. Therefore, innate effectorlarized, both in IFNgR2/2 and IFNgR1/2 mice. In chal-
lenge tumors of immunized IFNgR1/2 mice, angiogen- cells, which alone have rarely the ability to completely
eradicate a tumor (Hock et al., 1993), may be necessaryesis was strongly inhibited, which correlated with a rapid
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containing 1 mg/ml collagenase (Life Technologies) overnight atto kill residual tumor cells, e.g., those growing at the
08C and then 5 min at 378C in the presence of 0.1 mg/ml DNaseperiphery of the tumor. This is supported by the finding
I (Boehringer Mannheim, Germany). Single-cell suspensions werethat mice with a defective nitric oxide synthase and
prepared and subsequently tumor cells were cloned by limiting dilu-
diminished macrophage tumoricidal activity have a re- tion. The tumor cell lines and the mock- and IFNgR-transfected
duced ability to reject tumors (Hung et al., 1998). The variants were maintained in RPMI 1640 medium supplemented with
10% fetal calf serum. Three cell lines, Mc29.2, Mc51.9, and Mc54.1,requirement of residual tumor cell killing in addition to
were used in this study.antiangiogenesis is furthermore supported by the obser-
vation that half of the mice depleted of CD81 T cells
Plasmids and Cell Transfectionscould not reject the challenge tumor. However, because
The full-length mouse IFNgR cDNA was excised from the expressionthe potential of CD81 T cells to eliminate a tumor can
plasmid pHMGmGIFR (Hemmi et al., 1989) as an SmaI/SalI fragment,correlate with their ability to produce IFNg and TNF
blunt-ended, and then cloned into the SnaBI site of the retrovirus
rather than with their cytotoxic activity (Barth et al., vector pBabe (Morgenstern and Land, 1990). The resulting plasmid
1991), we can not exclude the possibility that inhibition pBabe-gR contains the IFNgR gene under the control of the viral
long terminal repeat promoter and a puromycin resistance geneof angiogenesis contributed to the antitumor effect me-
under the control of the SV40 promoter. Mc29.2, Mc51.9 and Mc54.1diated by CD81 T cells. (2) The inhibition of angiogenesis
cells were transfected with the plasmid pBabe-gR using a mamma-leads to a rapid necrosis in the center of the tumor
lian transfection kit (Stratagene GmbH, Heidelberg, Germany) and(Figure 7e), which should result in the release of high
selected in RPMI 1640 culture medium containing 4 mg/ml puromy-
amounts of tumor-derived antigens in a short time to cin, resulting in Mc29.2-gR, Mc51.9-gR, and Mc54.1-gR cell lines.
be taken up by APC. This might be important for activa- As controls, cells were also transfected with the empty plasmid
pBabe and selected for puromycin resistance, resulting in the mock-tion of CD41 T cells and an enhanced antitumor re-
transfected Mc29.2-m, Mc51.9-m, and Mc54.1-m cell lines.sponse. (3) A well-known dilemma in immunotherapy is
that cancer vaccines can be quite effective to prevent
Flow Cytometrythe growth of a challenge tumor, but they usually fail to
Cell surface IFNgR expression was determined by staining of cellsinduce tumor rejection when tumor-bearing animals are
with the rat anti-mouse IFNgR mAb (GR20, PharMingen, Hamburg,treated (Lollini and Forni, 1999). This must not be due
Germany) or an isotype-matched control mAb (R35±95, Phar-
to the failure of T cell activation in tumor-bearing mice, Mingen). PE-conjugated rabbit-anti-rat IgG2a (Jackson Immunore-
as the phenomenon of ªconcomitant immunityº sug- search Laboratories, West Grove, PA) was used as secondary anti-
body. To verify the specificity of the GR20 binding, tumor cells weregested. Rather, T cells activated in tumor-bearing mice
preincubated with 25 ng/ml murine IFNg (PharMingen) overnightare confronted with a well-vascularized tumor, and the
and then stained for IFNgR. For MHC class I expression, tumor cellseffect of antiangiogenesis may be less pronounced. The
cultured without or with 25 ng/ml IFNg for 24 hr were incubatedeffect of IFNg, alone or in combination with other factors,
with FITC-conjugated mAb anti-H-2Kb (AF6±88.5), anti-H-2Db
must not be restricted to inhibiting the growth of new (HK95), isotype-matched control mAb, mouse IgG2a (G155±178), or
blood vessels. Recently, we found that rejection of large mouse IgG2b (49.2) (PharMingen). All samples were analyzed with an
Epics-XL flow cytometer (Coulter Electronics, Hamburg, Germany).vascularized tumors by cyclophosphamide is mediated
by the destruction of tumor blood vessels, which also
required IFNgR expression on host cells (unpublished Tumor Growth In Vivo
The parental, mock-, or IFNgR-transfected tumor cells were washeddata).
in D-PBS and subcutaneously (s.c.) injected into IFNgR1/2 or
IFNgR2/2 mice at the indicated numbers in 0.2 ml D-PBS. TumorExperimental Procedures
growth was monitored every 2 to 3 days and mice bearing a tumor
of .10 mm in diameter were scored as tumor positive. For immuniza-Mice
tion of mice, 2 3 105 tumor cells were irradiated with 100 Gy andThe IFNgR-deficient (IFNgR2/2) mice congeneic to 129/Sv/Ev and
inoculated s.c. into mice. Two weeks later, mice were challengedcontrol wild type mice (IFNgR1/1) were kindly provided by M. Aguet
contralaterally by s.c. injection of parental tumor cells in numbers(Huang et al., 1993). Sex and age (6 to 12 weeks) matched control
as indicated.litter mates of the breeding between IFNgR2/2 and IFNgR1/2 mice
were used unless otherwise indicated. In some experiments, tumor
Tumor Fragment Transplantationrejection between IFNgR1/1 and IFNgR1/2 mice was compared,
Tumor fragments were removed from mice bearing primary MCA-which showed no phenotypical difference. The mutant IFNgR gene
induced tumors and passaged in nude mice as previously describedwas confirmed by polymerase chain reaction (PCR) using tail DNA
(Prehn and Main, 1957). Altogether, five primary tumors (two fromas described elsewhere. The primers used were located on exon V
IFNgR1/1 and three from IFNgR2/2 mice) were analyzed. For immuni-of the IFNgR gene: (sense) 59-CCC ATT TAG ATC CTA CAT ACG
zation, tumor fragments of 4 3 4 3 4 mm were s.c. transplantedAAA CAT ACG G-39 and (antisense) 59-TTT CTG TCA TGG AAA GGA
onto IFNgR1/1 and IFNgR2/2 mice (2±3/group). Tumors were cut outGGG ATA CAG-39. The PCR-amplified DNA fragment for the normal
by a surgical operation when they reached a size of 10 mm inIFNgR gene, including expression plasmid pBabe-gR, was 190 bp,
diameter at day 12±14. One week later, the mice were challengedand for the mutated allele, 1300 bp. A primer specific for the neomy-
contralaterally with a fragment (4 3 4 3 4 mm) of the same tumorcin phosphotransferase gene was also used to distinguish the
passaged in nude mice. The growth of the challenge tumor wasIFNgR1/1 and IFNgR1/2 mice: (neo) 59-CCT GCG TGC AAT CCA TCT
monitored every 2±3 days.TG-39. The amplified DNA fragment using the neo primer and the
IFNgR sense primer was about 460 bp for the mutant IFNgR allele.
T Cell Depletion
Groups of IFNgR1/1 mice were immunized with 2 3 105 irradiatedGeneration of Tumor Cell Lines from IFNgR2/2 Mice
Tumors were induced by intramuscular injection of 0.8 mg MCA in (100 Gy) Mc51.9 cells and challenged 14 days later contralaterally
with the same number of viable Mc51.9 cells. T cell subset depletionIFNgR2/2 mice and excised 21±23 weeks later at a size of 1.1±1.2
cm in diameter. Fragments of the primary tumors were grafted twice was done by intraperitoneal (i.p.) injection of 2 mg rat mAb GK1.5
(anti-CD4) or 2.43 (anti-CD8) in 0.5 ml D-PBS at day 23 and 14onto nude, twice onto IFNgR2/2, and twice onto IFNgR1/1 mice. The
in vivo passaged tumors were then isolated, minced, and incubated relative to challenge. Specific depletion was confirmed by flow cyto-
metric analysis of PBL at day 7, 14, and 21 by flow cytometricin trypsin-EDTA solution (Life Technologies, Karlsruhe, Germany)
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analysis using FITC-conjugated mAbs anti-CD4 (RM4±4) and anti- Barth, R.J., Mule, J.J., Spiess, P.J., and Rosenberg, S.A. (1991).
Interferon gamma and tumor necrosis factor have a role in tumorCD8 (53±6.7, PharMingen).
regressions mediated by murine CD81 tumor-infiltrating lympho-
cytes. J. Exp. Med. 173, 647±658.Analysis of T Cell Proliferation and Cytokine Production
Three to five mice per group were immunized twice with a 2 week Bennett, S.R., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F.,
interval by i.p. injection of 2 3 105 irradiated Mc51.9 cells. Five days and Heath, W.R. (1998). Help for cytotoxic-T-cell responses is medi-
later, spleen cells from immunized and, as control, naive IFNgR1/2 ated by CD40 signalling. Nature 393, 478±480.
or IFNgR2/2 mice were cultured at a concentration of 2 3 106/ml in Blankenstein, T., Qin, Z.H., UÈ berla, K., MuÈ ller, W., Rosen, H., Volk,
RPMI medium in 96-well plates (0.1ml/well) for 5 days. For specific H.D., and Diamantstein, T. (1991). Tumor suppression after tumor
T cell stimulation, Mc51.9 tumor cell lysate (made three times by cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med.
freeze/thaw) was added to spleen cells at a ratio of 1:40. T cell 173, 1047±1052.
proliferation was determined by a 12 hr 3H-thymidine incorporation
Boehm, U., Klamp, T., Groot, M., and Howard, J.C. (1997). Cellularassay. To determine IFNg production by immune spleen cells, super-
responses to interferon-gamma. Annu. Rev. Immunol. 15, 749±795.natants of the cell culture as described above were collected 5 days
Boon, T., Cerottini, J.C., Van den Eynde, B., van der Bruggen, P.,after in vitro restimulation with tumor cell lysates. A commercially
and Van Pel, A. (1994). Tumor antigens recognized by T lympho-available kit (OptEIA Mouse IFNg Set, PharMingen) was used for
cytes. Annu. Rev. Immunol. 12, 337±365.determination of IFNg concentration.
Cayeux, S., Richter, G., Noffz, G., Dorken, B., and Blankenstein, T.
Adoptive Transfer of Tumor Immunity (1997). Influence of gene-modified (IL-7, IL-4, and B7) tumor cell
Donor mice were immunized twice with a 2 week interval by i.p. vaccines on tumor antigen presentation. J. Immunol. 158, 2834±
injection of 2 3 105 irradiated Mc51.9 cells, and 5 days later spleen 2841.
cells were isolated. After the depletion of red blood cells by NH4Cl Coughlin, C.M., Salhany, K.E., Gee, M.S., LaTemple, D.C., Kotenko,
treatment, cells were cultured for 60 min at 378C to remove adherent S., Ma, X., Gri, G., Wysocka, M., Kim, J.E., Liu, L., et al. (1998). Tumor
cells. After washing in D-PBS, 3 3 107 cells (CD41, 30%±45%; CD81, cell responses to IFNgamma affect tumorigenicity and response to
10%±15%; and B2201, 40%±60%) were resuspended in 0.2 ml IL-12 therapy and antiangiogenesis. Immunity 9, 25±34.
D-PBS and intravenously (i.v.) injected into the tail vein of IFNgR1/2,
Dighe, A.S., Richards, E., Old, L.J., and Schreiber, R.D. (1994). En-IFNgR2/2, or SCID mice. Three days after the cell transfer, mice
hanced in vivo growth and resistance to rejection of tumor cellswere challenged with Mc51.9 cells and tumor growth was monitored.
expressing dominant negative IFN gamma receptors. Immunity 1,
447±456.
Bone Marrow Chimeric Mice
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H.,Freshly prepared bone marrow cells of 6- to 8-week-old female
Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R.C.IFNgR1/2 and IFNgR2/2 mice were injected i.v. into lethally irradiated
(1993). Vaccination with irradiated tumor cells engineered to secrete(10 Gy) recipient mice (5 3 106 cells/age- and sex-matched mice).
murine granulocyte-macrophage colony-stimulating factor stimu-The following groups of mice were included: IFNgR1/2 ! IFNgR1/2,
lates potent, specific, and long-lasting anti-tumor immunity. Proc.IFNgR1/2 ! IFNgR2/2, IFN-gR2/2 ! IFN-gR1/2, and IFN-gR2/2 !
Natl. Acad. Sci. USA 90, 3539±3543.IFN-gR2/2. Successful reconstitution of the hematopoietic system
was determined by flow cytometric analysis of peripheral blood Farber, J.M. (1990). A macrophage mRNA selectively induced by
mononuclear cells for IFNgR expression. Additionally, chimerism of gamma-interferon encodes a member of the platelet factor 4 family
mice was confirmed by PCR analysis of the IFNgR gene using tail of cytokines. Proc. Natl. Acad. Sci. USA 87, 5238±5242.
DNA that contained genomic DNA from both nonhematopoietic and Farrar, M.A., and Schreiber, R.D. (1993). The molecular cell biology
hematopoietic cells. Eleven weeks after bone marrow transplanta- of interferon-gamma and its receptor. Annu. Rev. Immunol. 11,
tion, mice were immunized with 2 3 105 irradiated Mc51.9 cells and 571±611.
challenged 2 weeks later with 1 3 106 Mc51.9 cells.
Folkman, J. (1998). Antiangiogenic gene therapy. Proc. Natl. Acad.
Sci. USA 95, 9064±9066.
Immunohistochemistry
Fransen, L., Van der Heyden, J., Ruysschaert, R., and Fiers, W.Isolation of tumor tissues, preparation of cryostat sections, and
(1986). Recombinant tumor necrosis factor: its effect and its syner-alkaline phosphatase immunostaining were done as described
gism with interferon-gamma on a variety of normal and transformed(Blankenstein et al., 1991). Here, 1 3 106 Mc51.9 cells were injected
human cell lines. Eur. J. Cancer Clin. Oncol. 22, 419±426.s.c. into naive or twice (with 2 3 105 irradiated Mc51.9 cells) immu-
Fujiwara, H., Fukuzawa, M., Yoshioka, T., Nakajima, H., and Ha-nized IFNgR1/2 or IFNgR2/2 mice at a shaved belly region, and tumor
maoka, T. (1984). The role of tumor-specific Lyt-112- T cells intissue was obtained after 4 and 6 days. The mAbs used for staining
eradicating tumor cells in vivo. I. Lyt-112- T cells do not necessarilywere anti-CD4 (GK1.5), anti-CD8 (53±6.7), anti-CD31 (MEC13.3),
require recruitment of host's cytotoxic T cell precursors for imple-anti-Gr-1 (RB6±8C5), anti-Mac-1 (M1/70), and isotype-matched con-
mentation of in vivo immunity. J. Immunol. 133, 1671±1676.trol mAbs (PharMingen). Alkaline phosphatase-conjugated goat
anti-rat IgG and rabbit anti-goat IgG were purchased from Jackson Greenberg, P.D. (1991). Adoptive T cell therapy of tumors: mecha-
Immunoresearch Laboratories. nisms operative in the recognition and elimination of tumor cells.
Adv. Immunol. 49, 281±355.
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